Gonococcal Infection Clinical Trial
Official title:
Clinical Evaluation of the Click Sexual Health Test for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) in Women
Verified date | September 2019 |
Source | Visby Medical |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is a multi-center study with a minimum of three CLIA-waived intended operator sites in the United States in which prospectively self-collected vaginal specimens obtained from subjects who are symptomatic or asymptomatic for CT, NG, or TV will be evaluated with the Click Sexual Health Test in a Clinical Laboratory Improvement Amendments (CLIA) waived setting. Subjects interested in participating in this study will be assessed for eligibility and asked to give informed consent and assent, if applicable, by the Investigational Review Board (IRB). Only those subjects who meet the inclusion and exclusion criteria may be enrolled in the study.
Status | Completed |
Enrollment | 309 |
Est. completion date | December 3, 2019 |
Est. primary completion date | December 3, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 14 Years to 99 Years |
Eligibility |
Inclusion Criteria: 1. Willing and able to give voluntary written informed consent and assent form (or the parental/legal guardian will provide parental permission) before any study-related procedure is performed. 2. Female at birth. (Pregnant and breastfeeding women are eligible). 3. Age greater than or equal to 14 years at the time of enrollment 4. Able to read and understand the procedural information provided for the study. 5. Able and willing to follow all study procedures, including performing self-collection of one vaginal swab and permitting a HCP to collect three additional vaginal swabs. Exclusion Criteria: 1. Have a medical condition, serious intercurrent illness, or other circumstance that, in the Investigator's judgement, could jeopardize the subjects's safety, or could interfere with study procedures. 2. Enrollment in the DMID 18-0024 and this study previously. 3. Use of antiperspirants and deodorants or the following vaginal products: douches, washes, lubricants, vaginal wipes, vaginal moisturizers, or feminine hygiene spray in the genital area, within 48 hours prior to enrollment. |
Country | Name | City | State |
---|---|---|---|
United States | Therafirst Medical Center | Fort Lauderdale | Florida |
United States | Planned Parenthood Gulf Coast | Houston | Texas |
United States | Lawrence OB/GYN Clinical Research, LLC | Lawrenceville | New Jersey |
United States | Planned Parenthood of the St. Louis Region and Southwest Missouri | Saint Louis | Missouri |
United States | Planned Parenthood North Central States | Saint Paul | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Visby Medical |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The percent sensitivity and specificity of the Click Device for detection of CT in self-collected vaginal specimens as compared to Patient Infected Status (PIS) using vaginal specimens collected by a qualified Health Care Provider (HCP) | up to 6 months | ||
Primary | The percent sensitivity and specificity of the Click Device for detection of NG in self-collected vaginal specimens as compared to PIS using vaginal specimens collected by a qualified HCP | up to 6 months | ||
Primary | The percent sensitivity and specificity of the Click Device for detection of TV in self-collected vaginal specimens as compared to PIS using vaginal specimens collected by a qualified HCP | up to 6 months | ||
Secondary | Usability will be measured by 5-point Likert scale responses, yes/no questions, and open text questions from study operators. | Questions are around three domains of interest: i) instructions, ii) operations, and iii) visual interpretation for the Click device for detection of CT, NG, and TV with patient self-collected specimens. The 5-point Likert scale will measure responses to questions in the form of: (1) Strongly Disagree, (2) Disagree, (3) Neutral, (4) Agree, and (5) Strongly Agree |
up to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03613649 -
Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects
|
Phase 1 | |
Completed |
NCT02961751 -
Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae
|
N/A | |
Completed |
NCT03073538 -
Screening of Gonococcal and Chlamydial Infections in the Third Trimester
|
||
Completed |
NCT04870138 -
Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
|
Phase 1 | |
Terminated |
NCT01291264 -
Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM]
|
Phase 4 | |
Completed |
NCT03852316 -
Clinical Study of a Diagnostic Device for NG, TV and CT in Women
|
N/A | |
Recruiting |
NCT04350138 -
Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection
|
Phase 2 | |
Completed |
NCT01849653 -
Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing
|
N/A | |
Completed |
NCT03840811 -
Experimental Human Infection With Neisseria Gonorrhoeae
|
Phase 1 |